Together, these data suggest that apelin or its receptor agonists could be of major interest in developing a potential treatment for COVID-19 through ACE and Ang-II suppression, as well as down-regulation of angiotensin receptor 1 (AT1R) and up-regulation of ACE2 [85] (Table 1). This evidence concerns the gene APLN and COVID-19.